Back in February, the FDA green-lighted Kalydeco to treat cystic fibrosis in patients with one of 8 distinct gating mutations, dramatically swelling the orphan drug's patient pool.
written on 27.06.2014
Vertex could snag 250 more Kalydeco patients with EMA nod
